Laboratory evaluation of ceftizoxime, a new parenteral cephalosporin.
(6,7R)-7-[(Z)-2-(2-Amino-4-thiazoyl)-2-methoxyiminoacetamido]-8-oxo-5-thia-1 -azabicyclo[4,2,0]oct-2-ene-2-carboxylate (ceftizoxime), a new parenteral cephalosporin, in more potently active in vitro and in vivo against various gram-negative bacilli including the opportunistic pathogens such as Enterobacter, Citrobacter species and Serratia marcescens than cephalosporins and cephamycins recently developed. Ceftizoxime is extremely stable to various types of beta-lactamases, and has a high ability to penetrate the outer membrane of gram-negative organisms.
D000818:Animals; D001419:Bacteria / Q000187:drug effects* / Q000378:metabolism; D001424:Bacterial Infections / Q000188:drug therapy; D015296:Ceftizoxime; D002463:Cell Membrane Permeability; D002510:Cephalosporinase / Q000378:metabolism; D002511:Cephalosporins / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D004355:Drug Stability; D008297:Male; D051379:Mice
D002511:Cephalosporins; D015296:Ceftizoxime; D002510:Cephalosporinase